GZMB and acute myeloid leukemia: The H22(scFv)-GrB hCFP targeting the CD64 receptor, a marker of a monocytic subtype of acute myeloid leukemia (AML), exhibits selective and specific cytotoxicity against CD64+ AML cells, while sparing CD64-cells [58].